Pretransplant splenomegaly debulking in myelofibrosis
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-08-23 — Sequential High-Dose Ruxolitinib and Low-Dose Splenic Irradiation for Pretransplant Management of Splenomegaly Before Allogeneic Hematopoietic Cell Transplantation With Fludarabine/Busulfan-Based Conditioning in Myelofibrosis.: Single-center retrospective series (n=9, 2020-2025) of sequential high-dose ruxolitinib then low-dose splenic irradiation demonstrates stepwise spleen shrinkage and supports adequate engraftment under Flu/Bu conditioning, establishing an initial evidence base for the combined debulking strategy. (novelty: 3)
Open questions
Related
Contributing findings
Sequential High-Dose Ruxolitinib and Low-Dose Splenic Irradiation for Pretransplant Management of Splenomegaly Before Allogeneic Hematopoietic Cell Transplantation With Fludarabine/Busulfan-Based Conditioning in Myelofibrosis.
23-aug-2026
novelty 3
per-area 3
introduces